Gilead wins EU backing to use remdesivir for COVID-19 in liver disease
Justin Sullivan/Getty Images News

Gilead Sciences (NASDAQ:GILD) announced Tuesday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), recommended marketing authorization for its antiviral Veklury (remdesivir) for COVID-19 in people with liver impairment.
The so-called positive opinion issued by EMAâs Committee for Medicinal Products for Human Use (CHMP) paves the way for the company to receive EU authorization to use the injection for COVID-19 across all stages of liver disease.

The CHMP recommendation will next be reviewed by the European Commission (EC) before a final decision on approval.
The EU is the hardest-hit region with liver disease in the world, Gilead (GILD) said, adding that case numbers are expected to rise across many countries.
Patients with liver diseases are highly vulnerable to COVID-19 and associated with an elevated morbidity and mortality risk.

The decision comes after the U.S. FDA expanded the label for Veklury, for use as a treatment for COVID-19 in liver disease.



More on Gilead 

Seeking Alphaâs Quant Rating on Gilead Sciences
Gilead Sciences: Searching For A Catalyst
Gilead says Trodelvy with Merckâs Keytruda controls lung cancer
Gilead raised to Buy at Bank of America on untapped potential
Gilead Sciences prices $2B senior unsecured notes in a public offering